Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12624000544572
Ethics application status
Approved
Date submitted
26/03/2024
Date registered
30/04/2024
Date last updated
27/10/2024
Date data sharing statement initially provided
30/04/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
A trial to assess the safety and tolerability of EBC-1013 Gel in participants with venous leg ulcers.
Scientific title
A Phase I First-in-Human multi-centre dose escalation study to assess the safety and tolerability of EBC-1013 Gel in participants with venous leg ulcers.
Secondary ID [1] 311771 0
QB1013C-H201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Venous Leg Ulcers 333275 0
Condition category
Condition code
Skin 329968 329968 0 0
Dermatological conditions
Skin 330114 330114 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This trial is designed to evaluate the safety and tolerability and to assess the systemic exposure following a single application of EBC-1013 Gel to Venous Leg Ulcers (VLUs) compared to placebo in participants with VLUs that have been present for between three months and 48 months, with size between 2.5 cm2 and 70.0 cm2.

In this First in Human trial, the following 5 dose concentrations of study drug will be tested:
Cohort 1: 0.1mg/g of EBC-1013 Gel
Cohort 2: 0.3mg/g of EBC-1013 Gel
Cohort 3: 0.6mg/g of EBC-1013 Gel
Cohort 4: 1.0mg/g of EBC-1013 Gel
Cohort 5: 1.5mg/g of EBC-1013 Gel.
One placebo controlled (Placebo Gel without EBC-1013 active substance) blinded participant will be included into each dose concentration cohort. In each of the above cohorts, EBC-1013 Gel (or placebo) will be administered at an application rate of 0.05 mL/cm2 of wound surface area.

A staggered sentinel approach will be used with a 7-day waiting period for the first two participants (one receiving EBC-1013 Gel, one receiving Placebo Gel) in each of the five dose concentration cohorts (i.e., 0.1, 0.3, 0.6, 1.0 and 1.5 mg/g).

Once all four participants (one placebo and three active) have received the application of EBC-1013 Gel or Placebo Gel for the current dose concentration level, and all four participants have completed their 7 day Dose Limiting Local Toxicity (DLLT) period, the Safety Review/Dose-Escalation Committee (SRDEC) will assess safety and tolerability of the four participants. If no DLLTs occurred, with the SRDEC’s approval, dose escalation will proceed to the next dose concentration by opening recruitment to the next cohort, and this process will be repeated. Participants from the previous cohort are not allowed to be recruited to the following cohorts.

The single dose of EBC-1013 Gel or Placebo Gel will be administered once only at the site. Application of EBC-1013 Gel or Placebo Gel will take <5 minutes. The participant will remain at the study site for post-treatment observation for at least 6 hours. They will then return to the study site for post-treatment follow-up visits on Days 1, 3, 7, 14 and 28.

As this product is only applied once, by the Investigator (or delegated staff) at the site, adherence/compliance to the intervention does not need to be monitored. Prior to administration, the VLU is assessed and measured by the site who calculate the volume to be administered based on the surface area. The Medical Monitor will review and approve dose calculations. After the dose has been applied, pharmacokinetic samples will be taken periodically to assess the interventions systemic exposure over time.
Intervention code [1] 328225 0
Treatment: Drugs
Comparator / control treatment
One placebo controlled (Placebo Gel without EBC-1013 active substance) blinded participant will be included into each of the five dose concentration cohorts.
Control group
Placebo

Outcomes
Primary outcome [1] 337730 0
To assess the overall safety and local tolerability of a single application of escalating doses of EBC-1013 Gel to Venous Leg Ulcers compared to placebo. Safety and tolerability will be assessed as a composite primary outcome.
Timepoint [1] 337730 0
Adverse event data will be collected from screening until day 28 post-treatment.

Physical examinations, vital signs, 12-lead ECGs and wound/toxicity assessments will be completed at all visits (screening, treatment day, and follow-up visits on days 1, 3, 7, 14 and 28).

Biochemistry and haematology safety assessments will be performed at Screening and follow-up visits on Days 1, 7, 14 and 28. Wound QoL 14 Questionnaire will be administered at Screening and again at the End of Study Visit on Day 28. NRS Wound Pain and Itch Scales will be completed at all visits from Screening to the End of Study Visit on Day 28.
Secondary outcome [1] 433003 0
To assess the systemic exposure resulting from a single application of escalating doses of EBC-1013 Gel.
Timepoint [1] 433003 0
PK sampling will be performed on Treatment Day as follows: pre-dose, and then at 5-mins, 15-mins, 30-mins, 1-hr, 2-hrs, 4-hrs and 6-hrs post-dose, and again at 24-hrs post-dose on Day 1
Secondary outcome [2] 433004 0
To determine the Anticipated Therapeutic Dose (ATD) or ATD range following a single application of EBC-1013 Gel when applied to Venous Leg Ulcers.
Timepoint [2] 433004 0
Assessment of DLLTs will be from the time of application (Day 0) to seven days after a single application (Day 7). The concentration(s) of EBC-1013 with less than or equal to 33% DLLTs will define the ATD or ATD range with acceptable safety and local tolerability.

Eligibility
Key inclusion criteria
- Male or female patient aged 18 years and above at screening
- Patient with a defined Venous Leg Ulcer (VLU), which has been present for at least
three months but no longer than 48 months at Screening,
- VLU is between 2.5 cm2 and an upper limit of 70.0 cm2 at Screening
- VLU is confirmed as venous in origin by venous doppler ultrasound and an Ankle Brachial Pressure Index (ABPI) > 0.8 to < 1.3 performed at Screening.
- Oedema of the leg with the VLU is assessed by the Investigator as adequately managed at Screening, with appropriate compression applied and maintained to manage oedema for at least 7 days prior to treatment.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History of non-compliance with standard of care treatment for VLU where the Investigator would consider that the patient would be unable to adhere to the study requirements.
- Suspicion of current neoplastic involvement in chronicity of wound.
- Patient has an active malignancy or history of malignancy related to the reference ulcer or other ulcers in the three years prior to screening.
- Significant hepatic or renal impairment
- Rheumatoid arthritis with known vasculitis.
- VLU has exposed tendons, ligaments, muscle or bone.
- VLU is assessed as deteriorating at Screening or has active infection requiring antibiotic treatment.
- Presence of active cellulitis on the leg with the VLU requiring antibiotic treatment.
- Debridement, skin grafts, negative pressure therapy, ultrasound therapy or systemic or topical growth factor therapy applied to the VLU within two weeks before screening.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Other
Other design features
A conventional, rule-based 3+3 dose escalation design will be used. The planned concentrations to be investigated in five dose concentration cohorts are 0.1, 0.3, 0.6, 1.0 and 1.5 mg/g of EBC-1013 Gel at an application rate of 0.05 mL/cm2 of wound surface area. One placebo controlled blinded participant will be included into each dose concentration cohort. A staggered sentinel approach will be used with a 7-day waiting period for the first two participants (one receiving EBC-1013 Gel, one receiving Placebo Gel) in each of the five dose concentration cohorts.
Phase
Phase 1
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
29/11/2024
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
35
Accrual to date
0
Final
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Recruitment hospital [1] 26286 0
Austin Health - Heidelberg Repatriation Hospital - Heidelberg West
Recruitment hospital [2] 26287 0
Princess Alexandra Hospital - Woolloongabba
Recruitment postcode(s) [1] 42257 0
3081 - Heidelberg West
Recruitment postcode(s) [2] 42258 0
4102 - Woolloongabba

Funding & Sponsors
Funding source category [1] 316104 0
Commercial sector/Industry
Name [1] 316104 0
QBiotics Group Limited
Country [1] 316104 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
QBiotics Group Limited
Address
Country
Australia
Secondary sponsor category [1] 318272 0
None
Name [1] 318272 0
Address [1] 318272 0
Country [1] 318272 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 314931 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 314931 0
Ethics committee country [1] 314931 0
Australia
Date submitted for ethics approval [1] 314931 0
02/04/2024
Approval date [1] 314931 0
02/05/2024
Ethics approval number [1] 314931 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 133174 0
A/Prof Michael Woodward
Address 133174 0
Austin Health (Heidelberg Repatriation Hospital), Medical and Cognitive Research Unit Level 3, Centaur Building 300 Waterdale Road Ivanhoe VIC 3079
Country 133174 0
Australia
Phone 133174 0
+61 3 9496 2388
Fax 133174 0
Email 133174 0
michael.woodward@austin.org.au
Contact person for public queries
Name 133175 0
Daniel Swart
Address 133175 0
QBiotics Group Limited, 3A/165 Moggill Road Taringa, Queensland, 4068
Country 133175 0
Australia
Phone 133175 0
+61 7 3870 8933
Fax 133175 0
Email 133175 0
enquiries@qbiotics.com
Contact person for scientific queries
Name 133176 0
Peter Schmidt
Address 133176 0
QBiotics Group Limited, 3A/165 Moggill Road Taringa, Queensland, 4068
Country 133176 0
Australia
Phone 133176 0
+61 7 3870 8933
Fax 133176 0
Email 133176 0
enquiries@qbiotics.com

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.